Compare Citius Pharmaceuticals Inc (CTXR) vs Funko Inc (FNKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Funko Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.69 (market cap $20.01M), while Funko Inc trades at $5.86 (market cap $332.33M). The key difference: Funko Inc is far larger — about 16.6× Citius Pharmaceuticals Inc's market cap, and Funko Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | FNKO | |
|---|---|---|
Market Cap | $20.01M | $332.33M |
Sector | Health | Consumer Staples |
52-Week High | $1.82 | $6.35 |
52-Week Low | $0.48 | $2.65 |
Enterprise Value | $16.23M | $552.98M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
Funko (FNKO) trades at $6.19, up 5.27% with bullish technical signals and strong recent earnings beats. The company shows improving fundamentals with Q2 2026 revenue growth of 7% to $207.7 million and raised EBITDA guidance. Despite negative net margins, the stock trades at attractive valuation multiples with P/S of 0.35 and EV/EBITDA of 6.46. Recent management changes and successful product launches support positive momentum.
Outlook remains cautiously optimistic with analyst consensus leaning toward hold/buy. Key opportunities include continued execution of the 'Make Culture POP!' strategy and margin improvement, while risks include persistent negative profitability and competitive pressures in the collectibles market. The stock presents value potential if operational improvements continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →
